To investigate the impact of common co-occurring genomic alterations on KRASG12C inhibitor combination strategies targeting distinct pathways, we screened a panel of KRASG12C-mutant NSCLC cell lines harboring diverse co-occurring mutations (Fig. S1A) with sotorasib alone or in combination with inhibitors targeting SHP2 (TNO 155), CDK4/6 (abemaciclib), PI3K (GDC-0941), BCL-XL/BCL-2 (navitoclax) or MCL-1 (AMG 176) (Fig. 1A). This evidence concerns the gene CDK4 and non-small cell lung carcinoma.